Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
Site Search
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
When participating in a clinical trial, nothing is more important than your safety. We go the extra mile when it comes to protecting study volunteers.
There are two main types of clinical studies in CF research. Both are important to move research forward and provide the best outcomes for people with CF.
There have never been more opportunities to help develop new drugs for cystic fibrosis than there are today. When you are deciding whether to participate in a